Lymphocyte Activating Gene 3 (LAG3) Antibody Market Report 2026

The lymphocyte activating gene 3 (lag3) antibody market size has grown rapidly in recent years. It will grow from $0.8 billion in 2025 to $0.91 billion in 2026 at a compound annual growth rate (CAGR) of 13.8%. The growth in the historic period can be attributed to limited availability of lag3 antibodies, reliance on traditional monoclonal antibody therapies, growing oncology pipeline, increasing academic and clinical research, regulatory approvals for early-stage antibodies.

The lymphocyte activating gene 3 (lag3) antibody market size is expected to see rapid growth in the next few years. It will grow to $1.53 billion in 2030 at a compound annual growth rate (CAGR) of 13.9%. The growth in the forecast period can be attributed to development of bispecific and tandem scfv antibodies, expansion of combination immunotherapies, increasing adoption in autoimmune and infectious disease treatment, rising investment in clinical trials and r&d, integration with personalized and precision medicine approaches. Major trends in the forecast period include rising adoption of lag3 antibodies in cancer immunotherapy, development of combination therapies with other immune checkpoint inhibitors, increased focus on autoimmune disease applications, expansion of clinical trials for infectious disease treatments, growth in humanized and bispecific antibody platforms.

The rising incidence of cancer is expected to drive the growth of the lymphocyte activating gene 3 (LAG3) antibody market in the future. Cancer incidence refers to the number of new cases occurring within a population during a specific period. This increase is largely linked to lifestyle-related risks such as poor diet, smoking, alcohol use, and exposure to environmental pollutants, all of which elevate the likelihood of developing cancer. LAG3 antibodies play a crucial role in treatment by restoring exhausted T cell function, thereby enhancing immune system activity against tumors. They improve patient outcomes by strengthening anti-tumor responses and offering new therapeutic options for advanced cancers. For example, in January 2024, the American Cancer Society reported that cancer cases rose to 2,001,140 compared to 1,958,310 in 2023, marking a 2.19% increase. Thus, the rising cancer incidence is fueling demand for LAG3 antibodies.

Companies in the LAG3 antibody market are prioritizing clinical trials to develop next-generation monoclonal antibodies that enhance immune activation and overcome resistance to existing immunotherapies. These advanced therapies are engineered to bind immune targets such as LAG-3 with greater specificity, stability, and potency, improving T-cell activation and anti-tumor responses. For instance, in February 2025, Bristol‑Myers Squibb Company, a US biopharmaceutical firm, shared updates on Opdualag (nivolumab + relatlimab‑rmbw), a first‑in‑class dual immunotherapy combining a LAG‑3‑blocking antibody with a PD‑1 inhibitor. Administered intravenously every four weeks, Opdualag blocks both LAG‑3-ligand and PD‑1-ligand interactions, preventing T‑cell exhaustion and promoting proliferation and cytokine secretion more effectively than PD‑1 monotherapy. Its fixed‑dose format (480 mg nivolumab + 160 mg relatlimab) makes it the first approved therapy to target LAG‑3 in combination, with applications for adult and pediatric patients (≥12 years) with unresectable or metastatic melanoma, offering improved progression‑free survival compared to PD‑1 inhibitors alone.

In June 2023, Chime Biologics Limited, a China-based contract development and manufacturing organization (CDMO), partnered with Leads Biolabs Inc. and BeiGene Ltd. to accelerate the development and production of innovative biologics, including monoclonal and bispecific antibody therapies. This collaboration aims to strengthen clinical pipelines and expand access to next-generation cancer immunotherapies. Leads Biolabs Inc., based in China, is developing LAG3 antibodies for cancer treatment, while BeiGene Ltd., a US biotechnology company, is advancing LAG3 antibodies to enhance immune checkpoint inhibition.

Major companies operating in the lymphocyte activating gene 3 (lag3) antibody market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Bristol-Myers Squibb Company, Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company Limited, Ono Pharmaceutical Co. Ltd., Xencor Inc., Innovent Biologics Inc., Zai Lab Limited, MacroGenics Inc., Akeso Inc., Agenus Inc., Alphamab Oncology, AnaptysBio Inc., Crescendo Biologics Ltd., EpimAb Biotherapeutics Inc., Shanghai Henlius Biotech Inc., Immutep Limited.

North America was the largest region in the lymphocyte activating gene 3 (LAG3) antibody market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lymphocyte activating gene 3 (lag3) antibody market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the lymphocyte activating gene 3 (lag3) antibody market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the LAG3 antibody market by increasing costs of imported monoclonal antibodies, bispecific antibodies, and lab reagents, affecting supply chains and treatment accessibility. Segments like humanized monoclonal antibodies and bispecific antibody platforms are most affected, particularly in North America, Europe, and Asia-Pacific regions including China and India. While tariffs have increased operational costs and slowed distribution, they have also promoted local manufacturing, domestic R&D investments, and innovation in cost-effective LAG3 antibody therapies.

The lymphocyte activating gene 3 (lag3) antibody market research report is one of a series of new reports that provides lymphocyte activating gene 3 (lag3) antibody market statistics, including lymphocyte activating gene 3 (lag3) antibody industry global market size, regional shares, competitors with a lymphocyte activating gene 3 (lag3) antibody market share, detailed lymphocyte activating gene 3 (lag3) antibody market segments, market trends and opportunities, and any further data you may need to thrive in the lymphocyte activating gene 3 (lag3) antibody industry. This lymphocyte activating gene 3 (lag3) antibody market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Lymphocyte-activating gene 3 (LAG3) antibodies are a class of therapeutic monoclonal antibodies that target the LAG-3 protein, an immune checkpoint receptor found on activated T cells. These antibodies work by blocking LAG-3, restoring T cell function, and enhancing immune responses, making them valuable for cancer immunotherapy and the treatment of chronic infections by overcoming T cell exhaustion.

The main types of LAG3 antibodies include monoclonal antibodies, polyclonal antibodies, and bispecific antibodies. Monoclonal antibodies are laboratory-produced molecules designed to bind specifically to a single target antigen, aiding the immune system in detecting and neutralizing harmful pathogens or diseased cells. These antibodies are available as monotherapy or combination therapy and act through mechanisms such as immune checkpoint inhibition, immunomodulatory activity, and co-stimulatory signaling. They are applied in areas including cancer immunotherapy, autoimmune diseases, and infectious diseases, with key end users comprising pharmaceutical and biotechnology companies, academic research institutions, and diagnostic laboratories.

The lymphocyte activating gene 3 (LAG3) antibody market consists of sales of relatlimab, favezelimab, eftilagimod alpha, biosimilars, antibody-drug conjugates, and combination therapy products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.